Project cooperationUpdated on 19 December 2025
Salivary Liquid Biopsy as a Human-Relevant NAM for Regulatory and Biomedical Research
progect manager at NSight Dynamics s.r.l.
Florence, Italy
About
NSight contributes to consortia addressing HORIZON-HLTH-2026-01-TOOL-03 by providing a human-relevant, non-invasive New Approach Methodology (NAM) based on advanced salivary liquid biopsy.
The NSight technology enables ultra-sensitive detection of molecular biomarkers in saliva, offering a scalable and ethically sustainable alternative or complement to traditional animal-based and invasive testing methods. The approach is particularly suited to regulatory testing, safety assessment and translational biomedical research, in line with the objectives of the topic.
Key contributions include:
-
Human-based NAM: non-invasive salivary liquid biopsy allowing repeated, longitudinal sampling directly in human subjects, increasing biological relevance and reducing reliance on animal models.
-
High-sensitivity molecular endpoints: detection of proteins and other molecular signals with sensitivity several orders of magnitude higher than conventional assays, supporting early and predictive safety and efficacy assessment.
-
Bridging experimental NAMs and regulatory decision-making: saliva-based biomarkers can be used to validate and contextualise data from in vitro, in silico and organ-on-chip models, strengthening translatability to humans.
-
Data integration and standardisation: generation of FAIR, interoperable biomarker datasets suitable for validation, comparison and potential regulatory acceptance.
-
Scalability and ethical sustainability: low-cost, stress-free sampling suitable for large cohorts and repeated measurements, aligned with the 3Rs principles and regulatory expectations for NAM adoption.
Within a consortium, NSight can act as technology provider and WP leader or co-leader for NAM development, biomarker validation and regulatory-relevant endpoint definition. By integrating salivary liquid biopsy into the NAM ecosystem, NSight strengthens the predictive power, human relevance and regulatory impact of next-generation biomedical research methodologies.
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
Multimodal AI Monitoring for Real-World Implementation of Multisectoral NCD Interventions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Victoria Barygina
progect manager at NSight Dynamics s.r.l.
Florence, Italy
Project cooperation
Translational Evidence Framework for Human-Relevant NAM Validation
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Emilien Nicolas
R&D Preclinical manager at CER Groupe
Aye, Belgium
Project cooperation
AI-enabled Multimodal Monitoring to Prevent Digital Technology–Related Mental Health Risks in Youth
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
Victoria Barygina
progect manager at NSight Dynamics s.r.l.
Florence, Italy